News and Trends 19 Dec 2018 Could We Use CRISPR to Light up Future Christmas Trees? Scientists in the UK have proposed a way to make bioluminescent Christmas trees using the gene editing tool CRISPR-Cas9. CRISPR-Cas9 is a revolutionary gene editing tool that makes it easier to edit the genome. For this reason, it is now a standard tool in research and development centers worldwide, and companies such as the German chemical […] December 19, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 26 Oct 2018 BASF Will Use CRISPR to Gene-Edit Crops and Microbes The German chemical giant BASF has obtained a non-exclusive license from the US Broad Institute for the use of CRISPR-Cpf1 gene-editing technology in agricultural and microbiological applications. CRISPR-Cas9 is a fast and easy technique for editing the genome that has gained worldwide fame. It has the potential for use in many applications such as in […] October 26, 2018 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 17 Oct 2018 Belgian Firm Will Develop Antibiotic Alternatives for Industrial Biotech Using CRISPR Syngulon will be developing antibacterial peptides using CRISPR/Cas9 gene editing technology thanks to an agreement with ERS Genomics, which licenses out CRISPR intellectual property in the EU. CRISPR technology is a hot topic in the biotech industry because it makes gene editing faster and easier than other techniques. This could make it very useful in […] October 17, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 25 Jul 2018 Could These Groundbreaking Therapies Make Conventional Antibiotics a Thing of the Past? With the rise of antimicrobial resistance across the globe, and with a dire lack of new antibiotics in the pipeline, more attention is going towards developing innovative treatments and technologies that kill superbugs in completely new ways. Here, we take a closer look at some of the most promising of these technologies emerging from the […] July 25, 2018 - 5 minutesmins - By Farhan Mitha Share WhatsApp Twitter Linkedin Email
News and Trends 16 Jul 2018 CRISPR-Cas9 Shown to Cause Previously Unseen DNA Damage Researchers at the Wellcome Trust Sanger Institute in the UK have found that gene editing with CRISPR-Cas9 can cause significantly more off-target damage to the DNA than previously thought. Published today in Nature Biotechnology, the study is the first to look at unexpected DNA changes caused by CRISPR across large regions of the genome. […] July 16, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 28 Jun 2018 The Race to Get CRISPR to the Clinic: Hope Versus Hype In 2016, German pharma giant Bayer took a bold step and decided to partner with CRISPR Therapeutics to form a company that could join the race to be first into the clinic with a CRISPR therapy. Peter Nell worked at Bayer for many years and was one of the founding team of Casebia Therapeutics. Now […] June 28, 2018 - 7 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jun 2018 Scientists Warn CRISPR Therapy Could Cause Cancer as First Human Trials Take Place A study at Karolinska Institutet in Sweden has revealed that CRISPR-Cas9 gene editing could favor mutations in the most common cancer-causing gene. What does it mean for the first CRISPR therapy trials in humans? CRISPR-Cas9 has taken the life sciences field by storm, making gene editing simpler and faster than ever. Although CRISPR-Cas9 gene […] June 11, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jun 2018 FDA Puts Clinical Trial for CRISPR Therapy on Hold The FDA has put a hold on CRISPR Therapeutics’ planned Phase I/II trial testing a CRISPR gene-editing therapy in patients with sickle cell disease, which will likely delay the use of CRISPR-based therapies in humans. CRISPR Therapeutics, headquartered in Basel, Switzerland, and its partner Vertex Pharmaceuticals will have to postpone their plans to start a Phase I/II trial […] June 1, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
In Depth 13 Mar 2018 The Most Important Battle in Gene Editing: CRISPR versus TALEN Despite all the hype, CRISPR is still not in the clinic as a standalone therapy or part of another. So where is it in biotech? CRISPR needs no introduction. Since the gene editing technology first entered the spotlight in 2012 with the promise of revolutionizing gene editing, it has made headlines as the subject of a furious […] March 13, 2018 - 6 minutesmins - By Editorial Team Share WhatsApp Twitter Linkedin Email
News and Trends 1 Mar 2018 Doudna and Charpentier Get Second CRISPR Patent in Europe Just a month after the European Patent Office revoked a CRISPR patent from the competitors of Doudna and Charpentier, they have been granted a second patent that covers a new form of the popular gene editing tool. The European Patent Office has granted CRISPR co-inventor Emmanuelle Charpentier, together with the University of California and the University […] March 1, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 28 Feb 2018 Could A More Precise CRISPR/Cas9 System Treat Huntington’s Disease? Polish researchers tested a new variant of CRISPR/Cas9 that increases the gene-editing system’s precision in targeting specific DNA sequences, such as the gene responsible for Huntington’s disease. CRISPR/Cas9 offers a means of editing genes by essentially ‘cutting and pasting’ sequences of DNA. A group of researchers at the Institute of Bioorganic Chemistry in Poland has developed […] February 28, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 16 Feb 2018 French Biotech Gets a CRISPR Patent for CAR-T Research Update (16/02/2018): On top of the European patent it got last July, Cellectis now also has two US patents to use CRISPR technology to make CAR-T cells. Cellectis has said it will offer licenses to companies that want to use CRISPR gene editing in T cells. Not just for inserting CAR antigens, but also other editions […] February 16, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email